- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Emeryville Today
By the People, for the People
Kyverna Therapeutics to Host Conference Call on New Data
The biotech company will discuss updates across its neuroimmunology portfolio.
Apr. 9, 2026 at 1:44pm
Got story updates? Submit your updates here. ›
Kyverna's research aims to unravel the complex interplay between the immune system and the central nervous system.Emeryville TodayKyverna Therapeutics, a clinical-stage biotechnology company, announced it will host a conference call to discuss new data across its neuroimmunology franchise. The call will provide updates on the company's pipeline of therapies targeting autoimmune and inflammatory diseases of the central nervous system.
Why it matters
Kyverna's work in neuroimmunology represents a promising area of research, as autoimmune and inflammatory conditions of the brain and nervous system remain difficult to treat. The company's ability to advance its pipeline and share meaningful data is an important milestone that could signal progress in addressing these complex disorders.
The details
During the conference call, Kyverna's leadership team will present data and provide updates on the company's ongoing clinical trials and preclinical research efforts within its neuroimmunology portfolio. This includes details on the development of novel cell therapies and small molecule candidates targeting neuroinflammation and autoimmune disorders of the central nervous system.
- The conference call will take place on April 9, 2026.
The players
Kyverna Therapeutics
A clinical-stage biotechnology company focused on developing novel cell therapies and small molecule candidates to treat autoimmune and inflammatory diseases, including those affecting the central nervous system.
What’s next
Investors and analysts will be able to access a replay of the conference call on Kyverna's website following the event.
The takeaway
Kyverna's focus on advancing its neuroimmunology pipeline represents an important step in the company's efforts to address complex autoimmune and inflammatory disorders of the brain and nervous system, an area of high unmet medical need.
